WO2018132533A1 - Bicyclic inhibitors of histone deacetylase - Google Patents

Bicyclic inhibitors of histone deacetylase Download PDF

Info

Publication number
WO2018132533A1
WO2018132533A1 PCT/US2018/013262 US2018013262W WO2018132533A1 WO 2018132533 A1 WO2018132533 A1 WO 2018132533A1 US 2018013262 W US2018013262 W US 2018013262W WO 2018132533 A1 WO2018132533 A1 WO 2018132533A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
disease
mixture
disorder
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/013262
Other languages
English (en)
French (fr)
Inventor
Nathan Oliver Fuller
John A. Lowe, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rodin Therapeutics Inc
Original Assignee
Rodin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodin Therapeutics Inc filed Critical Rodin Therapeutics Inc
Priority to ES18702014T priority Critical patent/ES2875562T3/es
Priority to US16/477,466 priority patent/US10793567B2/en
Priority to EP18702014.4A priority patent/EP3568135B1/en
Publication of WO2018132533A1 publication Critical patent/WO2018132533A1/en
Anticipated expiration legal-status Critical
Priority to US17/007,151 priority patent/US11225479B2/en
Priority to US17/559,488 priority patent/US11987580B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • HDAC histone deacetylases
  • Histone deacetylase inhibitors Histone deacetylase inhibitors. Adv Cancer Res, 91, 137-168, (2004). Moreover, recent evidence indicates that transcriptional dysregulation may contribute to the molecular pathogenesis of certain neurodegenerative disorders, such as Huntington's disease, spinal muscular atrophy, amyotropic lateral sclerosis, and ischemia. Langley, B., Gensert, J. M., Beal, M. F., Ratan, R. R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord, 4, 41-50, (2005).
  • HAT histone acetyltransferase
  • HDAC histone deacetylases
  • HDACl includes HDACl, HDAC2, HDAC3, and HDAC 8 and has homology to yeast Rpd3.
  • HDAC4, HDAC5, HDAC7, and HDAC9 belong to class Ila and have homology to yeast Hdal.
  • HDAC6 and HDAC 10 contain two catalytic sites and are classified as class lib.
  • Class III (the sirtuins) includes SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
  • HDACl 1 is another recently identified member of the HDAC family and has conserved residues in its catalytic center that are shared by both class I and class II deacetylases and is sometimes placed in class IV.
  • HDACs have been shown to be powerful negative regulators of long-term memory processes.
  • Nonspecific HDAC inhibitors enhance synaptic plasticity as well as long- term memory (Levenson et al., 2004, J. Biol. Chem. 279:40545-40559; Lattal et al., 2007, Behav Neurosci 121: 1125-1131; Vecsey et al., 2007, J. Neurosci 27:6128; Bredy, 2008, Learn Mem 15:460-467; Guan et al., 2009, Nature 459:55-60; Malvaez et al., 2010, Biol. Psychiatry 67:36-43; Roozendaal et al., 2010, J.
  • HDAC inhibition can transform a learning event that does not lead to long-term memory into a learning event that does result in significant long-term memory (Stefanko et al., 2009, Proc. Natl. Acad. Sci. USA 106:9447-9452). Furthermore, HDAC inhibition can also generate a form of long-term memory that persists beyond the point at which normal memory fails. HDAC inhibitors have been shown to ameliorate cognitive deficits in genetic models of Alzheimer's disease (Fischer et al., 2007, Nature 447: 178-182; Kilgore et al., 2010,
  • HDAC2 knockout mice exhibited increased synaptic density, increased synaptic plasticity and increased dendritic density in neurons.
  • HDAC2 deficient mice also exhibited enhanced learning and memory in a battery of learning behavioral paradigms. This work demonstrates that HDAC2 is a key regulator of synaptogenesis and synaptic plasticity. Additionally, Guan et al. showed that chronic treatment of mice with SAHA (an HDAC 1,2,3,6, 8 inhibitor) reproduced the effects seen in the HDAC2 deficient mice and rescued the cognitive impairment in the HDAC2
  • HDAC2 selective anti-viral activity
  • HDAC2 selective anti-viral activity
  • HDAC2 selective anti-proliferative activity
  • selective inhibition might be achieved by targeting specific HDAC isoforms such as HDAC2, in isolation, or as part of a functional multi-protein complex.
  • Such inhibition has the potential for enhancing cognition and facilitating the learning process through increasing synaptic and dendritic density in neuronal cell populations.
  • inhibition of specific HDACs, such as HDAC2 may also be therapeutically useful in treating a wide variety of other diseases and disorders.
  • HDAC HDAC2
  • Table 2 HDAC
  • One of the advantages of certain compounds described herein is that they possess improved brain exposure and have higher free brain concentration.
  • the brain Cmax exposure and projected free brain concentration of Compound 14 is 4-fold higher than comparator 1 (which only differs from Compound 14 by the absence of a methyl group. See Table 5) when comparator 1 data is scaled for comparison.
  • Certain compounds described herein provide enhanced safety parameters. For example, replacement of the bottom phenyl ring for heteraromatics afforded compounds with improved performance in colony forming unit assays, showing fewer effects on human erythroid and myeloid progenitors. See e.g., Table 4, Compounds 4, 8, 11, and 12 compared to comparator 2 and 3. Changing a 4-fluorophenyl group for a 2,4-difluorophenyl group also has a profound effect in safety parameters. See Table 4, Comparator 6 with Compound 9.
  • Certain compounds described herein perform well in a cell lysate assay employing an exogenous substrate to measure HDAC inhibitory activity. See Table 3.
  • Conditions which are treatable by the disclosed compounds include, but are not limited to, neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.
  • the terms "subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
  • the subject is a human in need of treatment.
  • salts of the compounds refer to nontoxic "pharmaceutically acceptable salts.”
  • Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
  • Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
  • pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphate
  • treatment refers to reversing, alleviating, reducing the likelihood of developing, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • an effective amount or “therapeutically effective amount” includes an amount of a compound described herein that will elicit a biological or medical response of a subject.
  • compounds and compositions described herein are useful in treating conditions associated with the activity of HDAC. Such conditions include for example, those described below.
  • CNS central nervous system
  • the provided compounds and compositions may be useful in treating a neurological disorder.
  • neurological disorders include: (i) chronic neurodegenerative diseases such as fronto- temporal lobar degeneration (frontotemporal dementia, FTD), FTD-GRN, familial and sporadic amyotrophic lateral sclerosis (FALS and ALS, respectively), familial and sporadic Parkinson's disease, Huntington's disease, familial and sporadic Alzheimer's disease, multiple sclerosis, muscular dystrophy, olivopontocerebellar atrophy, multiple system atrophy, Wilson's disease, progressive supranuclear palsy, diffuse Lewy body disease,
  • chronic neurodegenerative diseases such as fronto- temporal lobar degeneration (frontotemporal dementia, FTD), FTD-GRN, familial and sporadic amyotrophic lateral sclerosis (FALS and ALS, respectively), familial and sporadic Parkinson's disease, Huntington's disease, familial and sporadic Alzheimer's disease, multiple sclerosis, muscular dystrophy, olivopontocerebellar at
  • corticodentatonigral degeneration progressive familial myoclonic epilepsy, striatonigral degeneration, torsion dystonia, familial tremor, Down's Syndrome, Gilles de la Tourette syndrome, Hallervorden-Spatz disease, diabetic peripheral neuropathy, dementia pugilistica, AIDS Dementia, age related dementia, age associated memory impairment, and amyloidosis- related neurodegenerative diseases such as those caused by the prion protein (PrP) which is associated with transmissible spongiform encephalopathy (Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, scrapie, and kuru), and those caused by excess cystatin C accumulation (hereditary cystatin C angiopathy); and (ii) acute neurodegenerative disorders such as traumatic brain injury (e.g., surgery-related brain injury), cerebral edema, peripheral nerve damage, spinal cord injury, Leigh's disease, Guillain-Barre
  • encephalopathy hyperglycemia, hypoglycemia or direct trauma; pathologies arising as a negative side-effect of therapeutic drugs and treatments (e.g., degeneration of cingulate and entorhinal cortex neurons in response to anticonvulsant doses of antagonists of the NMDA class of glutamate receptor) and Wernicke-Korsakoff's related dementia.
  • Neurological disorders affecting sensory neurons include Friedreich's ataxia, diabetes, peripheral neuropathy, and retinal neuronal degeneration. Other neurological disorders include nerve injury or trauma associated with spinal cord injury.
  • Neurological disorders of limbic and cortical systems include cerebral amyloidosis, Pick's atrophy, and Rett syndrome.
  • neurological disorders include disorders of mood, such as affective disorders and anxiety; disorders of social behavior, such as character defects and personality disorders; disorders of learning, memory, and intelligence, such as mental retardation and dementia.
  • the disclosed compounds and compositions may be useful in treating schizophrenia, delirium, attention deficit hyperactivity disorder (ADHD), schizoaffective disorder, Alzheimer's disease, vascular dementia, Rubinstein-Taybi syndrome, depression, mania, attention deficit disorders, drug addiction, dementia, dementia including BPSD manifestations, agitation, apathy, anxiety, psychoses, personality disorders, bipolar disorders, unipolar affective disorder, obsessive-compulsive disorders, eating disorders, post-traumatic stress disorders, irritability, adolescent conduct disorder and disinhibition. They may also be useful for spontaneous, toxic, neoplastic, post-traumatic and post-infectious tinnitus and smelling impairment.
  • HATs histone acetyltransferases
  • HDACs histone deacetylases
  • the provided compounds and compositions may be useful for promoting cognitive function and enhancing learning and memory formation.
  • compositions described herein may also be used for treating fungal diseases or infections.
  • the compounds and compositions described herein may be used for treating inflammatory diseases such as stroke, rheumatoid arthritis, lupus erythematosus, ulcerative colitis and traumatic brain injuries (Leoni et al., PNAS, 99(5); 2995-3000(2002); Suuronen et al. J. Neurochem. 87; 407-416 (2003) and Drug Discovery Today, 10: 197-204 (2005).
  • inflammatory diseases such as stroke, rheumatoid arthritis, lupus erythematosus, ulcerative colitis and traumatic brain injuries
  • the compounds and compositions described herein may be used for treating a cancer caused by the proliferation of neoplastic cells.
  • cancers include e.g., solid tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphomas and the like.
  • cancers that may be treated by the compounds and compositions described herein include, but are not limited to: cardiac cancer, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, nervous system cancer, gynecological cancer, hematologic cancer, skin cancer, and adrenal gland cancer.
  • the compounds and compositions described herein are useful in treating cardiac cancers selected from sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma.
  • sarcoma angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma
  • myxoma rhabdomyoma
  • fibroma fibroma
  • lipoma lipoma
  • teratoma teratoma
  • the compounds and compositions described herein are useful in treating a lung cancer selected from bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma.
  • a lung cancer selected from bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma.
  • the compounds and compositions described herein are useful in treating a gastrointestinal cancer selected from esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), and large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma).
  • the compounds and compositions described herein are useful in treating a gastrointestinal cancer selected from esophag
  • kidney adenocarcinoma, Wilm's tumor
  • nephroblastoma lymphoma, leukemia
  • bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
  • the compounds and compositions described herein are useful in treating a liver cancer selected from hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
  • hepatoma hepatocellular carcinoma
  • cholangiocarcinoma hepatoblastoma
  • angiosarcoma hepatocellular adenoma
  • hemangioma hemangioma
  • the compounds described herein relate to treating, a bone cancer selected from osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma
  • osteogenic sarcoma osteosarcoma
  • fibrosarcoma fibrosarcoma
  • malignant fibrous histiocytoma chondrosarcoma
  • chondrosarcoma chondrosarcoma
  • Ewing's sarcoma malignant lymphoma (reticulum cell sarcoma)
  • multiple myeloma malignant giant cell tumor chordoma
  • osteocartilaginous exostoses benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
  • the compounds and compositions described herein are useful in treating a nervous system cancer selected from skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningio sarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma).
  • skull osteoma, hemangioma, granuloma, xanthoma, osteitis deformans
  • meninges meningioma, meningi
  • the compounds and compositions described herein are useful in treating a gynecological cancer selected from uterus (endometrial carcinoma), cervix
  • cervical carcinoma pre-tumor cervical dysplasia
  • ovaries ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa- thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).
  • the compounds and compositions described herein are useful in treating a skin cancer selected from malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and psoriasis.
  • the compounds and compositions described herein are useful in treating an adrenal gland cancer selected from neuroblastoma.
  • the compounds and compositions described herein are useful in treating cancers that include, but are not limited to: leukemias including acute leukemias and chronic leukemias such as acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML) and Hairy Cell Leukemia; lymphomas such as cutaneous T-cell lymphomas (CTCL),
  • noncutaneous peripheral T-cell lymphomas lymphomas associated with human T-cell lymphotrophic virus (HTLV) such as adult T-cell leukemia/lymphoma (ATLL), Hodgkin's disease and non-Hodgkin's lymphomas, large-cell lymphomas, diffuse large B-cell lymphoma (DLBCL); Burkitt's lymphoma; mesothelioma, primary central nervous system (CNS) lymphoma; multiple myeloma; childhood solid tumors such as brain tumors, neuroblastoma, retinoblastoma, Wilm's tumor, bone tumors, and soft-tissue sarcomas, common solid tumors of adults such as head and neck cancers (e.g., oral, laryngeal and esophageal), genito urinary cancers (e.g., prostate, bladder, renal, uterine, ovarian, testicular, rectal and colon), lung cancer, breast cancer, pancreatic cancer
  • the compounds and compositions described herein are useful in treating a condition in a subject selected from a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, psychiatric disorders, and neoplastic disease.
  • the compounds and compositions described herein are useful in treating a condition selected from a) a cognitive function disorder or impairment associated with Alzheimer's disease, Huntington's disease, seizure induced memory loss, schizophrenia, Rubinstein Taybi syndrome, Rett Syndrome, Fragile X, Lewy body dementia, vascular dementia, fronto-temporal lobar degeneration (frontotemporal dementia, FTD), FTD-GRN, ADHD, dyslexia, bipolar disorder and social, cognitive and learning disorders associated with autism, traumatic head injury, attention deficit disorder, anxiety disorder, conditioned fear response, panic disorder, obsessive compulsive disorder, posttraumatic stress disorder (PTSD), phobia, social anxiety disorder, substance dependence recovery, Age Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), ataxia, or
  • Parkinson's disease b) a hematological disease selected from acute myeloid leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia; c) a neoplastic disease; and d) an extinction learning disorder selected from fear extinction and post-traumatic stress disorder.
  • the condition treated by the compounds and compostions described herein is the condition is Alzheimer's disease, Huntington's disease, frontotemporal dementia, Freidreich's ataxia, post-traumatic stress disorder (PTSD), Parkinson's disease, depression, or substance dependence recovery.
  • the present disclosure provides a method of treating a condition described herein comprising administering to a subject an effective amount of a compound, or pharmaceutically acceptable salt described herein, or a composition thereof.
  • Subjects may also be selected to be suffering from one or more of the described conditions before treatment with one or more of the described compounds, or
  • compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. These compositions can be used to treat one or more of the conditions described above.
  • compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
  • provided compositions may be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the provided compound, such as e.g., 0.1 - 100 mg/kg body weight/day, can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
  • the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
  • the following describes an assay protocol for measuring the deacetylation of a peptide substrate by the enzymes HDAC2 or HDAC1.
  • Enzyme, substrate, and cofactors are combined in a well of a microtiter plate and incubated for 3 hours at 25 °C. At the end of the incubation, the reaction is quenched by the addition of an SDS-containing buffer. Substrate and product are separated and quantified electrophoretically using the microfluidic-based LabChip 3000 Drug Discovery System from Caliper Life Sciences.
  • the peptide substrate used in this assay is FAM- TSRHK(AC)KL-CONH2 (FAM is carboxyfluorescein).
  • Peptide should be >98% purity by Capillary Electrophoresis.
  • 1% DMSO from compound 1 ⁇ FAM-TSRHK(AC)KL-CONH2 5 nM HDAC Enzyme (specific activity may vary from lot-to-lot, and enzyme concentration may need to be adjusted to yield -10-20% conversion of substrate to product).
  • Negative control samples (0%- inhibition in the absence of inhibitor) and positive control samples (100%-inhibition, in the presence of 20 mM EDTA) are assembled in replicates of four and are used to calculate %-inhibition values for each compound at each concentration.
  • IC50 values of inhibitors are determined by fitting the inhibition curves (Pinh versus inhibitor concentration) by 4 parameter sigmoidal dose-response model using XLfit 4 software (IBDS).
  • SH-SY5Y cells (Sigma) were cultured in Eagle's Modified Essential Medium supplemented with 10% fetal bovine serum and pen/strep. Twenty-four hours prior to compound dosing 20 uL of cells were plated in white 384 well plates at a density of 1,500 cells/well. Compounds were serially diluted in neat DMSO and then diluted 1: 100 v/v into media without FBS and mixed. Media was removed from the plated cells and the diluted compounds in serum free media (1% v/v final DMSO) were added and incubated at 37°C for five hours.
  • HDAC2 IC50 HDAC2 IC50
  • Clonogenic progenitors of human erythroid CFU-E, BFU-E
  • CFU-GM granulocyte-monocyte
  • CFU-GEMM multipotential lineages
  • Clonogenic progenitors of the human erythroid (CFU-E and BFU-E) and myeloid (CFU-GM) lineages were set up in the methylcellulose-based media formulations described above. All compounds were added to the medium to give the final desired concentrations (10, 2 and 0.4 ⁇ ).
  • 5-Fluoro uracil Sigma Aldrich
  • Solvent control cultures containing no compound but 0.1% DMSO) as well as standard controls (containing no compound and no DMSO) were also initiated.
  • Photographs were taken of representative hematopoietic progenitor-derived colonies from various lineages, illustrating colonies in the presence of the solvent control as well as colonies in the presence of the test compounds.
  • CFU-E and BFU-E Erythroid
  • CFU-GM myeloid
  • CFU-GEMM multi-potential colony enumeration
  • 5-FU was used as a positive control for toxicity in these assays and the inhibitory effects obtained for this compound were exactly as expected.
  • the experiment was used to evaluate the potential effect of test compounds on human erythroid and myeloid progenitor proliferation in a methylcellulose-based medium.
  • the IC 50 values were calculated from XLfit. Dose response curves for erythroid and myeloid toxicity generated by XLfit. Finally, nonlinear regression curve fitting and IC50S + 95% CI, were calculated by Prism 7.0.-GEMM. Results are shown in Table 4.
  • Compound 1 was replaced a methyl in Comparator 2.
  • a similar improvement in safety profile was achieved by exchanging a 4-fluorophenyl group for a 2,4-difluorophenyl group in the pyrrolopyrazole series.
  • Compound 9 also realized an improved safety profile, particularly in the myeloid lineage.
  • IV Intravenous
  • PO Oral
  • mice were dosed in mice at either 10 mg/kg or 30 mg/kg PO, and were dosed at 1 mg/kg IV.
  • Plasma The animal was restrained manually at the designated time points, approximately 150 ⁇ ⁇ blood/time point was collected into K 2 EDTA tube via retro orbital puncture or cardiac puncture under anesthesia with Isoflurane. The blood sample was centrifuged (2000 g, 4°C, 5 min) to generate plasma within 30 min after bleeding.
  • Brain At the designated time points, a mid-line incision was made in the animals scalp and the skin was retracted. Using small bone cutters and rongeurs, removed the skull overlying the brain. Removed the brain using a spatula and rinse with cold saline. Placed the brain in screw-top tubes, and then stored the tubes under -70°C until analysis.
  • alkyl groups ethyl or methyl
  • the carbon position between the pyrimidine nitrogens led to increased half life (with both rV and PO dosing) and decreased clearance (IV), as well as improved brain exposure relative to unsubstituted counteparts (e.g., Comparator 1 and Comparator 6).
  • Clonogenic progenitors of the human megakaryocyte (CFU-Mk) lineage were assessed in a semi-solid, collagen-based matrix containing rhIL-3 (10 ng/niL), rhIL-6 (10 ng/mL) and rhTpo (50 ng/niL).
  • Normal human bone marrow light density cells (lot #0170525), derived from normal bone marrow (NorCal Biologies, California), were stored at -152 C until required for the assay. On the day of the experiment, the cells were thawed rapidly, the contents of each vial was diluted in 10 mL of Iscove's modified Dulbecco's medium containing 10% fetal bovine serum (IMDM + 10% FBS) and washed by centrifugation (approximately 1200 r.p.m. for 10 minutes, room temperature). The supernatant was discarded and the cell pellets resuspended in a known volume of IMDM + 10% FBS. A cell count (3% glacial acetic acid) and viability assessment (trypan blue exclusion test) was performed for the bone marrow sample.
  • IMDM + 10% FBS 10% fetal bovine serum
  • Clonogenic progenitors of the human megakaryocytic (CFU-Mk) lineages were set up in the media formulation described above. All compounds were added to the medium to give the final desired concentrations (20, 6.67. 2.22, 0.74, 0.25, and 0.082 ⁇ ). Solvent control cultures (containing no compound but 0.2% DMSO), as well as a standard control (containing no compound and no DMSO), were also initiated.
  • the megakaryocyte progenitor assay allows for the evaluation of more primitive progenitors, detected by the presence of large colonies (CFU- Mk >50), the intermediate progenitors (CFU-Mk 21-49), detected by the presence of medium sized colonies, as well as the most mature progenitors (CFU-Mk 3-20), detected by the presence of small colonies.
  • the total CFU-Mk value is the sum of the CFU-Mk (3-20), CFU- Mk (21-49) and CFU-Mk (>50). IC 5 o values are determined based on the total CFU-Mk.
  • Results are shown in Table 6 (IC50 shown for 6-point dose response; % control remaining @ 10 uM dose shown for 3-point dose response).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2018/013262 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase Ceased WO2018132533A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES18702014T ES2875562T3 (es) 2017-01-11 2018-01-11 Inhibidores bicíclicos de histona desacetilasa
US16/477,466 US10793567B2 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase
EP18702014.4A EP3568135B1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase
US17/007,151 US11225479B2 (en) 2017-01-11 2020-08-31 Bicyclic inhibitors of histone deacetylase
US17/559,488 US11987580B2 (en) 2017-01-11 2021-12-22 Bicyclic inhibitors of histone deacetylase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762445022P 2017-01-11 2017-01-11
US62/445,022 2017-01-11
US201762555298P 2017-09-07 2017-09-07
US62/555,298 2017-09-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/477,466 A-371-Of-International US10793567B2 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase
US17/007,151 Continuation US11225479B2 (en) 2017-01-11 2020-08-31 Bicyclic inhibitors of histone deacetylase

Publications (1)

Publication Number Publication Date
WO2018132533A1 true WO2018132533A1 (en) 2018-07-19

Family

ID=61074595

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2018/013262 Ceased WO2018132533A1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase
PCT/US2018/013260 Ceased WO2018132531A1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2018/013260 Ceased WO2018132531A1 (en) 2017-01-11 2018-01-11 Bicyclic inhibitors of histone deacetylase

Country Status (27)

Country Link
US (7) US10793567B2 (https=)
EP (2) EP3568135B1 (https=)
JP (1) JP6756925B2 (https=)
KR (1) KR102526032B1 (https=)
CN (1) CN110290789B (https=)
AU (1) AU2018207402B2 (https=)
BR (1) BR112019014235A2 (https=)
CA (1) CA3049443A1 (https=)
CY (1) CY1125287T1 (https=)
DK (1) DK3570834T3 (https=)
ES (2) ES2909086T3 (https=)
HR (1) HRP20220223T1 (https=)
HU (1) HUE057849T2 (https=)
IL (1) IL267953B2 (https=)
LT (1) LT3570834T (https=)
MA (1) MA47305A (https=)
MD (1) MD3570834T2 (https=)
MX (1) MX394242B (https=)
PL (1) PL3570834T3 (https=)
PT (1) PT3570834T (https=)
RS (1) RS62959B1 (https=)
SG (1) SG11201906164RA (https=)
SI (1) SI3570834T1 (https=)
SM (1) SMT202200131T1 (https=)
TW (1) TWI770104B (https=)
WO (2) WO2018132533A1 (https=)
ZA (1) ZA201904459B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016413A1 (en) * 2019-07-23 2021-01-28 Alkermes, Inc. Synthesis of bicyclic inhibitors of histone deacetylase
US12043607B2 (en) 2021-12-03 2024-07-23 Tango Therapeutics, Inc. HDAC inhibitors and therapeutic use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
CA3143188A1 (en) * 2019-06-13 2020-12-17 Dana-Farber Cancer Institute, Inc. Hdac3 catalytic inhibitor development and uses thereof
CN110734924B (zh) * 2019-10-25 2020-10-23 山东大学第二医院 一种抑郁症检测、治疗和预后靶点及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2017007756A1 (en) * 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase

Family Cites Families (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112824A (en) 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP3169413B2 (ja) 1992-01-31 2001-05-28 エーザイ株式会社 イミダゾール誘導体
DE4212748A1 (de) 1992-04-16 1993-10-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
GB9500580D0 (en) 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
DK0808312T3 (da) 1995-02-02 2001-02-12 Smithkline Beecham Plc Indolderivater som 5-HT-receptorantagonist
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5886186A (en) 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof
JP2000507590A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
JPH1149676A (ja) 1997-07-31 1999-02-23 Geron Corp ピリジン系テロメラーゼ阻害剤
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
AU3876600A (en) 1999-03-16 2000-10-04 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
JP2004531456A (ja) 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾールを用いてアレルギーを治療する方法
WO2002026708A1 (en) 2000-09-27 2002-04-04 Toray Industries, Inc. Nitrogen-containing compounds and ccr3 inhibitors containing the same as the active ingredient
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
ATE409181T1 (de) 2001-05-08 2008-10-15 Univ Yale Proteomimetische verbindungen und verfahren
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
JP4167848B2 (ja) 2002-04-10 2008-10-22 広栄化学工業株式会社 ビアリール化合物の製造法
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1594512A4 (en) 2003-02-11 2007-07-11 Kemia Inc COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
DE602004017316D1 (de) 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
TWI287567B (en) 2003-07-30 2007-10-01 Chi Mei Optoelectronics Corp Light-emitting element and iridium complex
US20050049241A1 (en) 2003-08-08 2005-03-03 Carruthers Nicholas I. Pyridyl piperazinyl ureas
CA2535665A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
BRPI0509298A (pt) 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
CA2575081C (en) 2004-07-26 2013-05-07 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
US20090018145A1 (en) 2004-10-19 2009-01-15 Compass Pharmaceuticals Llc Compositions and their use as anti-tumor agents
WO2006051311A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
CN101128454A (zh) 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DK1838674T3 (da) 2005-01-14 2011-06-14 Chemocentryx Inc Heteroarylsulfonamider og CCR2
EP1683796A1 (en) 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
WO2006080884A1 (en) 2005-01-27 2006-08-03 Astrazeneca Ab Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
EP1879548A2 (en) 2005-05-13 2008-01-23 Ciba Specialty Chemicals Holding Inc. Process for coloring keratin fibers comprising metal complexes
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
JP2008545744A (ja) 2005-06-02 2008-12-18 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト フェニルアルキル置換ヘテロアリール誘導体
EP1893607A4 (en) 2005-06-09 2010-07-21 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
WO2006137772A1 (en) 2005-06-20 2006-12-28 Astrazeneca Ab New physical form of n,n´- disubstituted oxabispidines
US7456195B2 (en) 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
FR2892412B1 (fr) 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
CA2635209A1 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Fluorinated arylamide derivatives
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
JP2007283748A (ja) 2006-03-23 2007-11-01 Fujifilm Corp 光記録媒体および可視情報記録方法
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
JPWO2007125984A1 (ja) 2006-04-28 2009-09-10 日本農薬株式会社 イソキサゾリン誘導体及び有害生物防除剤並びにその使用方法
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
JP2009535388A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
US20100022547A1 (en) 2006-06-02 2010-01-28 Brandeis University Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
BRPI0714440A2 (pt) 2006-07-21 2013-04-24 Irm Llc composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
EP2051964A4 (en) 2006-07-28 2012-03-07 Univ Connecticut INHIBITORS OF FATTY ACID AMIDHYDROLASE
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US20080076813A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
JP2010519174A (ja) 2006-09-18 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔの複素環阻害薬およびその使用方法
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2008053913A1 (en) 2006-11-02 2008-05-08 Shionogi & Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
US20080145816A1 (en) 2006-12-15 2008-06-19 Hershey Adrienne A Yankauer suction device
MX2009006613A (es) 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179067A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
JP2008179068A (ja) 2007-01-25 2008-08-07 Fujifilm Corp 光記録媒体および可視情報記録方法
PT2114900T (pt) 2007-01-31 2019-01-17 Ym Biosciences Australia Pty Compostos à base de tiopirimidina e as suas utilizações
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
US20100120839A1 (en) 2007-04-20 2010-05-13 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2008139152A1 (en) 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
AU2008259804B2 (en) 2007-06-05 2013-04-18 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2170339B1 (en) 2007-06-27 2014-10-15 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
WO2009022171A1 (en) 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
US8354383B2 (en) 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
US8440830B2 (en) 2007-09-19 2013-05-14 4Sc Ag Tetrahydro-fused pyridines as histone deacetylase inhibitors
EP2197552B1 (en) * 2007-09-19 2012-11-21 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
CA2702950A1 (en) 2007-10-16 2009-04-23 Northeastern University Methods and compounds for modulating cannabinoid activity
US20090156825A1 (en) 2007-11-26 2009-06-18 Heidebrecht Jr Richard W Fluorescent compounds that bind to histone deacetylase
WO2009078992A1 (en) 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
ES2429129T3 (es) 2008-07-11 2013-11-13 Irm Llc 4-Fenoximetilpiperidinas como moduladores de la actividad de GPR119
WO2010007756A1 (ja) 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
JP5524215B2 (ja) 2008-09-19 2014-06-18 ファイザー・インク 抗菌剤として有用なヒドロキサム酸誘導体
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
WO2010088574A1 (en) 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
WO2010108921A1 (en) 2009-03-27 2010-09-30 Nerviano Medical Sciences S.R.L. N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
CN102388052A (zh) 2009-04-01 2012-03-21 诺瓦提斯公司 调节硬脂酰基-CoA去饱和酶的螺环衍生物
MX2011011800A (es) 2009-05-07 2012-01-27 Gruenenthal Gmbh Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
JP2011006408A (ja) 2009-05-29 2011-01-13 Sumitomo Chemical Co Ltd 神経栄養因子の活性が関与する疾患の治療または予防剤
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AU2011232347B2 (en) 2010-03-24 2015-08-06 Musc Foundation For Research Development Compositions and methods for the treatment of degenerative diseases
AU2011236155B2 (en) 2010-04-06 2014-01-16 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
EP2588465B1 (en) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US20140018538A1 (en) 2010-08-20 2014-01-16 President And Fellows Of Harvard College High-valent palladium fluoride complexes and uses thereof
JP2012107001A (ja) 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
WO2012074050A1 (ja) 2010-12-01 2012-06-07 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板、液晶表示装置、及び化合物
JP5992435B2 (ja) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 循環からの生体分子の除去剤
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CN103339110A (zh) 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012117097A1 (en) 2011-03-03 2012-09-07 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
SG193331A1 (en) 2011-03-18 2013-10-30 Lupin Ltd Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2836338C (en) 2011-05-16 2022-05-03 Koninklijke Philips N.V. Tetrazine derivatives used in bio-orthogonal drug activation
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
JP2014521616A (ja) 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体
US20130029961A1 (en) 2011-07-26 2013-01-31 Gruenenthal Gmbh Substituted Heterocyclic Aza Compounds
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
CN103827092A (zh) 2011-08-12 2014-05-28 巴斯夫欧洲公司 N-硫代邻氨基苯甲酰胺化合物及其作为农药的用途
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
BR112014006940A2 (pt) 2011-09-23 2017-04-04 Bayer Ip Gmbh uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
KR101749611B1 (ko) 2012-04-12 2017-06-21 벌시테크 리미티드 유기발광다이오드용 백금(ⅱ) 착화합물
WO2013163404A1 (en) 2012-04-27 2013-10-31 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
WO2013180193A1 (ja) 2012-05-31 2013-12-05 住友化学株式会社 縮合複素環化合物
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
CN106905297A (zh) 2012-06-15 2017-06-30 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
WO2014005125A2 (en) 2012-06-29 2014-01-03 Biotium, Inc. Fluorescent compounds and uses thereof
US9605002B2 (en) 2012-07-18 2017-03-28 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US9738623B2 (en) 2012-08-06 2017-08-22 The General Hospital Corporation Curcumin analogs
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014055955A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
CN104994857A (zh) 2012-10-11 2015-10-21 格吕伦塔尔有限公司 Tspo介导的疾病和/或障碍的治疗和/或预防
JP2014101353A (ja) 2012-10-26 2014-06-05 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
HK1215030A1 (zh) 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
FI2922574T3 (fi) 2012-11-22 2023-08-11 Tagworks Pharmaceuticals B V Kemiallisesti pilkkoutuva ryhmä
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
EP2928891B1 (en) 2012-12-04 2019-02-20 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
CN103864754B (zh) 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
WO2014164704A2 (en) 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2903813C (en) 2013-03-15 2023-08-29 Epizyme, Inc. Carm1 inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
AR095570A1 (es) 2013-03-20 2015-10-28 Hoffmann La Roche Derivados de urea
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104163791B (zh) 2013-05-20 2017-05-03 湖南化工研究院 N‑吡啶（杂）芳酰胺类化合物及其制备方法与应用
CN104163792B (zh) 2013-05-20 2017-04-12 湖南化工研究院 N‑吡啶酰胺类化合物及其制备方法与应用
CN105473578A (zh) 2013-05-24 2016-04-06 加州生物医学研究所 用于治疗抗药性和持续性结核病的化合物
CN105682665A (zh) 2013-05-30 2016-06-15 华盛顿大学 用于治疗细菌性感染的化合物和方法
CN104232076B (zh) 2013-06-10 2019-01-15 代表亚利桑那大学的亚利桑那校董会 具有改进的发射光谱的磷光四齿金属络合物
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
GB2516303A (en) 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
CN114380700A (zh) 2013-10-08 2022-04-22 卢庆彬 用于靶向化疗的非铂基抗癌化合物
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
CN103601718A (zh) 2013-12-05 2014-02-26 江西天人生态股份有限公司 一类基于鱼泥丁受体的邻甲酰氨基苯甲酰胺衍生物及其制备方法和用途
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
CN103804312B (zh) 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
WO2015142903A2 (en) 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
GB201405002D0 (en) 2014-03-20 2014-05-07 Isis Innovation Fluorination method
US11691997B2 (en) 2014-04-09 2023-07-04 Lumiphore, Inc. Macrocycles
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
US20170349540A1 (en) 2014-07-28 2017-12-07 The General Hospital Corporation Histone deacetylase inhibitors
CA2992846A1 (en) 2014-08-04 2016-02-11 Fundacion Para La Investigacion Medica Aplicada Novel compounds for use in cognition improvement
CA2958193C (en) 2014-08-18 2024-02-27 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016100711A1 (en) 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
WO2016173557A1 (zh) 2015-04-30 2016-11-03 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017027984A1 (en) 2015-08-20 2017-02-23 Simon Fraser University Compounds and methods for treatment of cancer by inhibiting atg4b and blocking autophagy
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
EP3362436B1 (en) 2015-09-14 2021-06-30 Universiteit Antwerpen Process for the catalytic directed cleavage of amide-containing compounds
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CA3015484C (en) 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
CA3015817A1 (en) 2016-03-09 2017-09-14 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10385031B2 (en) 2016-11-23 2019-08-20 Regenacy Pharmaceuticals, Llc Substituted piperazines as selective HDAC1,2 inhibitors
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
CN106946890A (zh) 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
IL279920B2 (en) 2018-07-13 2024-06-01 Alkermes Inc Bicyclic inhibitors of histone deacetylase
IL279940B2 (en) 2018-07-13 2024-06-01 Alkermes Inc Histone deacetylase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
WO2017007756A1 (en) * 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ALBERINI, PHYSIOL. REV., vol. 89, 2009, pages 121 - 145
BARRETT, LEARN MEM, vol. 15, 2008, pages 460 - 467
BOUSIGES ET AL., PLOS ONE, vol. 8, no. 3, 2013, pages e57816
BREDY, LEARN MEM, vol. 15, 2008, pages 460 - 467
CITROME, PSYCHOPHARMACOL. BULL., vol. 37, no. 2, 2003, pages 74 - 88
DRUG DISCOVERY TODAY, vol. 10, 2005, pages 197 - 204
F. F. WAGNER ET AL: "Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers", CHEMICAL SCIENCE, vol. 6, no. 1, 1 January 2015 (2015-01-01), United Kingdom, pages 804 - 815, XP055300906, ISSN: 2041-6520, DOI: 10.1039/C4SC02130D *
FISCHER ET AL., NATURE, vol. 447, 2007, pages 178 - 182
GUAN ET AL., NATURE, vol. 459, 2009, pages 55 - 60
JOHANNESSEN, CNS DRUG REV., vol. 9, 2003, pages 199 - 216
KILGORE ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 35, 2010, pages 870 - 880
KOUZARIDES, CELL, vol. 128, 2007, pages 693 - 705
LANGLEY, B.; GENSERT, J. M.; BEAL, M. F.; RATAN, R. R.: "Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents", CURR DRUG TARGETS CNS NEUROL DISORD, vol. 4, 2005, pages 41 - 50, XP009048265, DOI: doi:10.2174/1568007053005091
LATTAL ET AL., BEHAV NEUROSCI, vol. 121, 2007, pages 1125 - 1131
LEONI ET AL., PNAS, vol. 99, no. 5, 2002, pages 2995 - 3000
LEVENSON ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 40545 - 40559
MALVAEZ ET AL., BIOL. PSYCHIATRY, vol. 67, 2010, pages 36 - 43
MARKS, P. A.; RICHON, V. M.; MILLER, T.; KELLY, W. K.: "Histone deacetylase inhibitors", ADV CANCER RES, vol. 91, 2004, pages 137 - 168, XP009163027
MARKS, P.; RIFKIND, R. A.; RICHON, V. M.; BRESLOW, R.; MILLER, T.; KELLY, W. K.: "Histone deacetylases and cancer: causes and therapies", NAT REV CANCER, vol. 1, 2001, pages 194 - 202, XP002392334, DOI: doi:10.1038/35106079
ROOZENDAAL ET AL., J. NEUROSCI., vol. 30, 2010, pages 5037 - 5046
STEFANKO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 106, 2009, pages 9447 - 9452
SUURONEN ET AL., J. NEUROCHEM., vol. 87, 2003, pages 407 - 416
TSANKOVA ET AL., NAT. NEUROSCI., vol. 9, 2006, pages 519 - 525
TSANKOVA, N. M.; BERTON, O.; RENTHAL, W.; KUMAR, A.; NEVE, R. L.; NESTLER, E. J.: "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action", NAT NEUROSCI, vol. 9, 2006, pages 519 - 525
VECSEY ET AL., J. NEUROSCI, vol. 27, 2007, pages 6128

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016413A1 (en) * 2019-07-23 2021-01-28 Alkermes, Inc. Synthesis of bicyclic inhibitors of histone deacetylase
US12043607B2 (en) 2021-12-03 2024-07-23 Tango Therapeutics, Inc. HDAC inhibitors and therapeutic use thereof

Also Published As

Publication number Publication date
KR20190104389A (ko) 2019-09-09
SMT202200131T1 (it) 2022-05-12
AU2018207402A1 (en) 2019-07-18
MX2019008302A (es) 2019-12-02
US11225479B2 (en) 2022-01-18
ES2909086T3 (es) 2022-05-05
BR112019014235A2 (pt) 2020-03-17
MD3570834T2 (ro) 2022-04-30
US10696673B2 (en) 2020-06-30
TWI770104B (zh) 2022-07-11
CN110290789A (zh) 2019-09-27
US20200148678A1 (en) 2020-05-14
TW201831183A (zh) 2018-09-01
US10793567B2 (en) 2020-10-06
JP2020504156A (ja) 2020-02-06
SI3570834T1 (sl) 2022-05-31
US20210122748A1 (en) 2021-04-29
ES2875562T3 (es) 2021-11-10
US10519149B2 (en) 2019-12-31
IL267953A (en) 2019-09-26
IL267953B2 (en) 2023-02-01
EP3570834B1 (en) 2021-12-22
MA47305A (fr) 2019-11-27
EP3570834A1 (en) 2019-11-27
WO2018132531A1 (en) 2018-07-19
CY1125287T1 (el) 2023-06-09
AU2018207402B2 (en) 2023-09-28
US11286256B2 (en) 2022-03-29
HRP20220223T1 (hr) 2022-04-29
JP6756925B2 (ja) 2020-09-16
PL3570834T3 (pl) 2022-05-23
US20220340560A1 (en) 2022-10-27
US20180215759A1 (en) 2018-08-02
KR102526032B1 (ko) 2023-04-25
US20190337953A1 (en) 2019-11-07
SG11201906164RA (en) 2019-08-27
CN110290789B (zh) 2022-10-18
US11987580B2 (en) 2024-05-21
RS62959B1 (sr) 2022-03-31
EP3568135A1 (en) 2019-11-20
CA3049443A1 (en) 2018-07-19
PT3570834T (pt) 2022-03-01
ZA201904459B (en) 2021-02-24
EP3568135B1 (en) 2021-04-07
MX394242B (es) 2025-03-24
HUE057849T2 (hu) 2022-06-28
IL267953B (en) 2022-10-01
LT3570834T (lt) 2022-03-10
DK3570834T3 (en) 2022-02-28
US20210053964A1 (en) 2021-02-25
US9951069B1 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
US11987580B2 (en) Bicyclic inhibitors of histone deacetylase
US11912702B2 (en) Substituted pyridines as inhibitors of histone deacetylase
TWI809146B (zh) 組蛋白去乙醯酶雙環抑制劑
HK40017120A (en) Bicyclic inhibitors of histone deacetylase
HK40017120B (en) Bicyclic inhibitors of histone deacetylase
HK40031661B (en) Bicyclic inhibitors of histone deacetylase
HK40020413B (en) Bicyclic inhibitors of histone deacetylase
HK40020413A (en) Bicyclic inhibitors of histone deacetylase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18702014

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018702014

Country of ref document: EP

Effective date: 20190812